Patents by Inventor Irving H. Fox
Irving H. Fox has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230312727Abstract: Antibody formulations are described comprising a mixture of an anti-?4?7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.Type: ApplicationFiled: October 13, 2022Publication date: October 5, 2023Inventors: Willow Diluzio, Phoung M. Nguyen, Csanad M. Varga, Vaithianathan Palaniappan, Jason Brown, Irving H. Fox, Catherine Scholz, Erica Helen Jenkins, Maria Rosario
-
Publication number: 20220370617Abstract: Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-?4?7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-?4?7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.Type: ApplicationFiled: February 22, 2022Publication date: November 24, 2022Inventors: Willow Diluzio, Nobel T. Truong, Csanad M. Varga, Vaithianathan Palaniappan, Jason Brown, Irving H. Fox, Catherine Scholz
-
Publication number: 20210340261Abstract: Antibody formulations are described comprising a mixture of an anti-?4?7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.Type: ApplicationFiled: April 23, 2021Publication date: November 4, 2021Inventors: Willow Diluzio, Phoung M. Nguyen, Csanad M. Varga, Vaithianathan Palaniappan, Jason Brown, Irving H. Fox, Catherine Scholz, Erica Helen Jenkins, Maria Rosario
-
Publication number: 20200377601Abstract: Antibody formulations are described comprising a mixture of an anti-?4?7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.Type: ApplicationFiled: February 11, 2020Publication date: December 3, 2020Inventors: Willow Diluzio, Phoung M. Nguyen, Csanad M. Varga, Vaithianathan Palaniappan, Jason Brown, Irving H. Fox, Catherine Scholz, Erica Helen Jenkins, Maria Rosario
-
Publication number: 20200206353Abstract: Methods for maintaining clinical remission of ulcerative colitis in a human patient are described comprising administration of an antibody that has binding specificity for human alpha4beta7 integrin using a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-alpha4beta7 antibody in vivo.Type: ApplicationFiled: December 23, 2019Publication date: July 2, 2020Inventors: Irving H. Fox, Catherine Scholz
-
Publication number: 20190231878Abstract: Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-?4?7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-?4?7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.Type: ApplicationFiled: December 3, 2018Publication date: August 1, 2019Inventors: Jason Brown, Willow Diluzio, Irving H. Fox, Vaithianathan Palaniappan, Catherine Scholz, Nobel T. Truong, Csanad M. Varga
-
Publication number: 20180346578Abstract: Antibody formulations are described comprising a mixture of an anti-a4b7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-a4b7 antibody in vivo.Type: ApplicationFiled: June 15, 2018Publication date: December 6, 2018Applicant: Millennium Pharmaceuticals, Inc.Inventors: Willow Diluzio, Phuong M. Nguyen, Csanad M. Varga, Vaithianathan Palaniappan, Jason Brown, Irving H. Fox, Catherine Scholz, Erica Helen Jenkins, Maria Rosario
-
Patent number: 10143752Abstract: Methods for maintaining clinical remission of ulcerative colitis in a human patient are described comprising administration of an antibody that has binding specificity for human ?4?7 integrin using a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.Type: GrantFiled: July 20, 2016Date of Patent: December 4, 2018Assignee: Millennium Pharmaceuticals, Inc.Inventors: Irving H. Fox, Catherine Scholz
-
Publication number: 20180327497Abstract: Antibody formulations are described comprising a mixture of an anti-?4?7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.Type: ApplicationFiled: May 18, 2018Publication date: November 15, 2018Applicant: Millennium Pharmaceuticals, Inc.Inventors: Willow Diluzio, Phuong M. Nguyen, Csanad M. Varga, Vaithianathan Palaniappan, Jason Brown, Irving H. Fox, Catherine Scholz, Erica Helen Jenkins, Maria Rosario
-
Publication number: 20180289811Abstract: Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-?4?7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-?4?7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.Type: ApplicationFiled: June 21, 2018Publication date: October 11, 2018Applicant: Millennium Pharmaceuticals, Inc.Inventors: Irving H. Fox, Catherine Scholz
-
Publication number: 20180207279Abstract: Methods for maintaining clinical remission of ulcerative colitis in a human patient are described comprising administration of an antibody that has binding specificity for human alpha4beta7 integrin using a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-alpha4beta7 antibody in vivo.Type: ApplicationFiled: March 20, 2018Publication date: July 26, 2018Inventors: Irving H. Fox, Catherine Schloz
-
Patent number: 10004808Abstract: Methods for inducing clinical remission of ulcerative colitis in a human patient are described comprising administration of an antibody that has binding specificity for human ?4?7 integrin using a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.Type: GrantFiled: July 20, 2016Date of Patent: June 26, 2018Assignee: MILLENNIUM PHARMACEUTICALS, INC.Inventors: Irving H. Fox, Catherine Scholz
-
Patent number: 9663579Abstract: Methods for achieving clinical response of Crohn's disease in a human patient are described comprising administration of an antibody that has binding specificity for human ?4?7 integrin using a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.Type: GrantFiled: July 20, 2016Date of Patent: May 30, 2017Assignee: Millennium Pharmaceuticals, Inc.Inventors: Irving H. Fox, Catherine Scholz
-
Publication number: 20170002078Abstract: Methods for inducing clinical remission of ulcerative colitis in a human patient are described comprising administration of an antibody that has binding specificity for human ?4?7 integrin using a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.Type: ApplicationFiled: July 20, 2016Publication date: January 5, 2017Applicant: Millennium Pharmaceuticals, Inc.Inventors: IRVING H. FOX, CATHERINE SCHOLZ
-
Publication number: 20160340431Abstract: Methods for maintaining clinical remission of ulcerative colitis in a human patient are described comprising administration of an antibody that has binding specificity for human ?4?7 integrin using a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.Type: ApplicationFiled: July 20, 2016Publication date: November 24, 2016Applicant: Millennium Pharmaceuticals, Inc.Inventors: Irving H. Fox, Catherine SCHOLZ
-
Publication number: 20160340432Abstract: Methods for achieving clinical response of Crohn's disease in a human patient are described comprising administration of an antibody that has binding specificity for human ?4?7 integrin using a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.Type: ApplicationFiled: July 20, 2016Publication date: November 24, 2016Applicant: Millennium Pharmaceuticals, Inc.Inventors: Irving H. Fox, Catherine Scholz
-
Publication number: 20140377251Abstract: Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-?4?7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-?4?7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 anti body in vivo.Type: ApplicationFiled: May 2, 2012Publication date: December 25, 2014Applicant: MILLENNIUM PHARMACEUTICALS, INC.Inventors: Willow Diluzio, Nobel T. Truong, Csanad M. Varga, Vaithianathan Palaniappan, Jason Brown, Irving H. Fox, Catherine Scholz
-
Publication number: 20140341885Abstract: Antibody formulations are described comprising a mixture of an anti-?4?7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.Type: ApplicationFiled: May 2, 2012Publication date: November 20, 2014Applicant: MILLENNIUM PHARMACEUTICALS, INCInventors: Willow Diluzio, Phuong M. Nguyen, Csanad M. Varga, Vaithianathan Palaniappan, Jason Brown, Irving H. Fox, Catherine Scholz, Erica Helen Jenkins, Maria Rosario
-
Publication number: 20120282249Abstract: Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-?4?7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-?4?7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-?4?7 antibody in vivo.Type: ApplicationFiled: May 2, 2012Publication date: November 8, 2012Inventors: Irving H. Fox, Catherine Scholz
